Aprepitant
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Aprepitant: Evaluation Halted — Critical Data Gaps Identified
Summary
Aprepitant (DrugBank: DB00673) is an NK1 (neurokinin-1) receptor antagonist approved internationally for prevention of chemotherapy-induced nausea and vomiting (CINV). This Evidence Pack (v4, 2026-04-20) is incomplete: the TxGNN prediction pipeline has returned no predicted indications, and two critical data gaps remain unresolved. No meaningful repurposing evaluation can proceed until these gaps are remediated.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | NK1 receptor antagonist / antiemetic (CINV prevention) |
| Predicted New Indication | Pending — TxGNN predictions not yet available |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A |
| Taiwan Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why No Evaluation Is Possible Yet
Currently, detailed mechanism of action data is not available in this Evidence Pack (Data Gap DG002, severity: High). Based on publicly known information, Aprepitant is an NK1 receptor antagonist approved by FDA and EMA for prevention of CINV and postoperative nausea and vomiting (PONV). It is commonly co-administered with corticosteroids and 5-HT₃ antagonists as part of antiemetic prophylaxis regimens.
More critically, TxGNN has not produced any predicted indications for Aprepitant in this Evidence Pack (predicted_indications array is empty). Without a TxGNN prediction score and a target indication, the core repurposing hypothesis cannot be evaluated.
Two data gaps must be resolved before this candidate can advance:
| Gap ID | Item | Severity | Impact | Remediation |
|---|---|---|---|---|
| DG001 | TFDA package insert warnings / contraindications | Blocking | Cannot complete S1 safety screening | Download TFDA insert PDF and parse |
| DG002 | Mechanism of action (MOA) | High | Cannot perform mechanism-relevance analysis | Query DrugBank API for DB00673 |
Taiwan Market Information
Aprepitant has zero authorized licenses in Taiwan. It is not currently marketed domestically.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The Evidence Pack contains no TxGNN predictions and two unresolved data gaps of Blocking/High severity; a repurposing evaluation report cannot be meaningfully generated at this stage.
To proceed, the following is needed:
- Run TxGNN prediction pipeline — generate ranked indication predictions for Aprepitant and populate
predicted_indications - Resolve DG001 — download and parse the TFDA (or EMA/FDA) package insert PDF to extract key warnings and contraindications
- Resolve DG002 — query DrugBank API for Aprepitant's mechanism of action data
- Re-generate Evidence Pack — once all gaps are resolved, produce a v5 Evidence Pack with complete data and resubmit for full report generation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.